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Abstract
Bacteria in biofilms have higher antibiotic tolerance than their planktonic counterparts. A major outstanding question is the
degree to which the biofilm-specific cellular state and its constituent genetic determinants contribute to this hyper-tolerant
phenotype. Here, we used genome-wide functional profiling of a complex, heterogeneous mutant population of
Pseudomonas aeruginosa MPAO1 in biofilm and planktonic growth conditions with and without tobramycin to
systematically quantify the contribution of each locus to antibiotic tolerance under these two states. We identified large
sets of mutations that contribute to antibiotic tolerance predominantly in the biofilm or planktonic setting only, offering
global insights into the differences and similarities between biofilm and planktonic antibiotic tolerance. Our mixed
population-based experimental design recapitulated the complexity of natural biofilms and, unlike previous studies,
revealed clinically observed behaviors including the emergence of quorum sensing-deficient mutants. Our study revealed a
substantial contribution of the cellular state to the antibiotic tolerance of biofilms, providing a rational foundation for the
development of novel therapeutics against P. aeruginosa biofilm-associated infections.
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Introduction
Biofilms are ubiquitous in nature, and the majority of human
bacterial infections involve biofilms [1,2]. While biofilms contain
cells with a heterogeneous range of states [3], on average, bacteria
in biofilms have a much higher—up to 1000-fold— antibiotic
tolerance than their planktonic counterparts [4].
A case in point is P. aeruginosa, the major cause of morbidity in
cystic fibrosis patients [5] and a frequent cause of nosocomial
infections [6]. In the lungs of cystic fibrosis patients, P. aeruginosa
persists as a biofilm, which further enhances the organism’s
inherently high antibiotic tolerance [7]. Aerosolized tobramycin,
an aminoglycoside, is commonly prescribed to combat P.
aeruginosa infections in cystic fibrosis patients [8]. However,
during the course of treatment, the drug’s efficacy typically
decreases as adaptive mutations accumulate leading to the
emergence of hyper-tolerant mutants [9,10]. In an attempt to
combat the problem, aminoglycoside tolerance, and more
specifically tobramycin tolerance, has been studied extensively in
both the biofilm and planktonic states in P. aeruginosa. A number
of factors are thought to be involved including oxidative
phosphorylation [11,12,13], lipopolysaccharide (LPS) composition
[11], cyclic di-guanosine monophosphate (c-di-GMP) levels [14],
quorum sensing [15], and membrane permeability [11].
In spite of the vast amount of work on the subject, our
understanding of the connection between biofilms and antibiotic
tolerance remains incomplete. For example, while bacteria in
biofilms are generally known to be more tolerant of antimicrobial
agents, it is still not clear if strains that are better at biofilm
formation necessarily have higher antibiotic tolerance.
To date, several loci have been linked to aminoglycoside
tolerance in Pseudomonas. Some, including ndvB, pvrR, arr, and
the PA1874-PA1877 efflux pump genes, modulate aminoglycoside
tolerance only in the biofilm state [14,16,17,18] and others such as
amgRS, mexXY-oprM, and the pel locus have a general impact
on tolerance independent of the cellular state [19,20,21,22]. The
identified genes, many of which are strain specific [17,19], belong
to a variety of different biological processes including efflux
pumping (PA1874–7 and mexXY-oprM), polysaccharide biosyn-
thesis (pel and ndvB), and signaling (arr, pvrR, amgRS). These
examples, however, do not provide a comprehensive perspective of
antibiotic tolerance in different cellular states, and the extent to
which planktonic and biofilm antibiotic tolerances share similar
mechanisms and genetic components has not been systematically
explored. Additionally, the most commonly used antibiotic
sensitivity assays, which are carried out in monocultures of
homogenous mutants, do not capture the complex interactions
between mutants and the heterogeneous populations from which
they emerge.
In order to address these shortcomings, we designed an
experimental approach capable of identifying mutants with
enhanced antibiotic tolerance in the context of a diverse population.
To this end, we adapted and optimized a transposon mutagenesis
and genetic footprinting technology [23] for P. aeruginosa and used it
to quantify the contribution of each P. aeruginosa locus to tobramycin
tolerance in the biofilm and planktonic states. Our novel
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clinical isolates, such as the high fitness of quorum sensing-deficient
mutants [24].
Our results indicate that large sets of loci contribute to antibiotic
tolerance predominantly in the biofilm or planktonic setting only
and reveal how the cellular state and multi-cellular interactions
combine to impact the response to an antibiotic challenge.
Results
Fitness Landscape of Biofilm Formation Capacity and
Antibiotic Tolerance
To explore the genetic basis of the emergence of antibiotic
tolerant mutants in P. aeruginosa biofilms, we allowed a library of
transposon insertion mutants to form a biofilm en masse and then
challenged the population with tobramycin (Figure 1). Then, for
each locus, we used the relative abundance of transposon insertions
before and after the selection as an indicator of the contribution of
that locus to biofilm-mediated tobramycin tolerance. To distinguish
loci that modulate antibiotic tolerance specifically in biofilms from
those that have planktonic effects, modify biofilm formation
capacities, or alter growth rates in the media itself, we performed
similar experiments on biofilms in the absenceof drug (Bio-ND)and
in planktonic cultures with and without tobramycin (Pla-TOB and
Pla-ND, respectively). Biofilms of wild-type-cells exposed to the
chosen tobramycin concentration (the Bio-TOB condition) had 2%
the number of viable cells as untreated biofilms, while planktonic
cultures had only 0.02% the number of viable cells of their
unexposed counterparts (Figure S1). A comparative analysis of the
fitness landscape in the four experimental conditions indicated that
large sets of genes contribute to antibiotic tolerance primarily in
biofilmorplanktonicconditionsonly.Furthermore,evenamongthe
many genes that modulate tobramycin tolerance in both planktonic
cultures and biofilms, the relative contribution of individual loci
frequently varies as a function of cellular state.
The level of antibiotic challenge was chosen to be sufficiently
severe to enable the identification of clinically relevant pathways
Author Summary
Biofilms, matrix-enclosed surface-colonized communities
of bacteria, are extremely resistant to antimicrobial agents,
withstanding concentrations of antibiotics orders of
magnitude higher compared to free-swimming planktonic
cells. This is a well-established characteristic of infections
caused by the opportunistic pathogen Pseudomonas
aeruginosa, the major cause of morbidity in cystic fibrosis
patients and a frequent cause of nosocomial infections,
and Pseudomonas infections generally persist despite the
use of long-term antibiotic therapy. Nonetheless, the
genetic basis of the hyper-tolerance of biofilms to
antimicrobial agents is poorly understood. In this study,
we use a genome-wide genetic footprinting technology to
systematically quantify the contribution of each locus in P.
aeruginosa to antibiotic tolerance in both biofilm and
planktonic states. Comparing and contrasting the ge-
nome-wide genetic profile of these two physiological
states revealed that large sets of genes modulate antibiotic
tolerance as a function of the cellular state.
Figure 1. Experimental design. For biofilm experiments, a transposon insertion library was given 24 hours to form a biofilm on a plastic slide in
media lacking tobramycin. Next, the slide and the attached biofilm were moved to fresh media with tobramycin for another 24 hours, and then the
biofilm was allowed to recover in fresh, drug-free media for an additional 24 hours. After repeating the drug exposure and recovery a second time,
the biofilm was disrupted and the cells were collected. Abundance of individual mutants was determined using microarray-based genetic
footprinting. Planktonic experiments were similar except the slide was not included and cultures were shaken. Tobramycin was omitted from ‘‘no
drug’’ controls. In all cases, containers were sealed. See Materials and Methods for details.
doi:10.1371/journal.ppat.1002298.g001
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Necessarily, this design constraint limited our ability to discover
loci in which genetic perturbations increase antibiotic sensitivity
and led us to focus on the set of mutants of above-average fitness.
Overall, we found that transposon insertions within or in the
vicinity of any of 586 open reading frames (ORFs) (Figure 2A; see
Dataset S3 for a complete list of these ORFs) cause a reproducible,
condition-dependent fitness increase in at least one experimental
setting (see Protocol S1).
Most transposon insertions identified here likely cause null
alleles, while others possibly act by increasing the expression of
neighboring genes [23]. Phenotypes similar to those observed in
the identified mutants could arise naturally by similar transposition
events or by a range of other alterations including nonsense
mutations or frameshift-causing indels. Therefore, the identified
mutations have clear implications for the emergence of hyper-
tolerant mutants within pathologic biofilms treated with drug.
Regardless of the exact mechanism employed, the results indicate
that P. aeruginosa has a large mutational target for increasing
antibiotic tolerance.
In order to identify biological pathways that contribute to the
condition-specific fitnesses observed, we first partitioned the 586
genes identified into six clusters (labeled C1 through C6 as shown
in Figure 2A) based on their fitness profiles. Next, we used iPAGE
[25] to search for functional categories enriched or depleted in
each cluster (Figure 2B). Disruptions in many genes whose
products function in oxidative phosphorylation were, for example,
beneficial in the presence of tobramycin in both the biofilm and
planktonic challenges (cluster C4, Figure 2B). The role of the
electron transport chain in causing oxidative stress and ultimately
death following exposure to lethal concentrations of bactericidal
antibiotics was previously described [26], and increased amino-
glycoside tolerance resulting from disruption of the pathway
components in the planktonic state has been observed in a wide
range of species including P. aeruginosa [11,26,27].
Although disruptions of oxidative phosphorylation components
are beneficial in both biofilm and planktonic conditions, unlike the
Pla-TOB condition, oxidative phosphorylation mutants do not
dominate the population in the Bio-TOB condition. In particular,
mutants with transposon insertions in the main NADH dehydro-
genase operon (PA2637-PA2649) appear significantly lower in lists
of the most abundant insertions (Wilcoxon matched pairs signed-
rank test p-value =0.033) following Bio-TOB selections compared
to Pla-TOB selections.
iPAGE did not identify any significant functional enrichments
specific to either the Pla-TOB or Bio-TOB challenges (clusters C2
Figure 2. Gene- and pathway-level analysis of fitness profiles. Comparative analysis of genome-wide footprinting data suggests that
transposon insertions in or near 586 genes (see Dataset S3 for a complete list of these genes) cause reproducible, condition-dependent behavior that
increases fitness in at least one setting (see Protocol S1). (A) The 586 genes (rows) were arranged using K-means clustering into six clusters shown on
the left (C1 through C6). The hybridization scores shown for each gene were mean-centered and normalized to a standard deviation of one. This
commonly used normalization puts each gene’s fitness profile on a similar scale and facilitates comparison between the different conditions. Yellow
indicates those conditions where mutants with transposons in or near the indicated gene underwent the greatest increases in abundance. Blue
indicates conditions where transposons in or near the same gene were either deleterious or were slightly beneficial and resulted in a comparatively
small increase in abundance. Column labels indicate the experimental condition: Bio-ND and Bio-TOB refer to transposon insertion libraries grown as
biofilms and treated with no drug or tobramycin, respectively, and Pla-ND and Pla-TOB refer to libraries grown planktonically without or with
tobramycin. Two biological replicates were performed in each condition and numbers indicate the repetition number. Gene names and annotations
are in Dataset S3. (B) iPAGE was used to look for enrichment and depletion of functional categories (rows) among clusters C1 through C6 plus the set
of genes not in any cluster (columns). Red (green) indicates that genes in the cluster were enriched (depleted) for the indicated category.
doi:10.1371/journal.ppat.1002298.g002
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aeruginosa genome’s annotation. However, we observed functional
enrichment/depletion patterns in classes not involving tobramy-
cin. For example, disruptions in genes involved in type-IV pili
biosynthesis were beneficial in biofilms in the absence of
tobramycin but not in any of the other conditions (cluster C5).
The existence of numerous mutants with high fitness in the Bio-
ND but not the Bio-TOB selection indicates that the high biofilm-
formation capacity is not, in itself, sufficient to increase antibiotic
tolerance. Type-IV pili mediate twitching motility [28], and failure
of a population to reduce twitching motility results in abnormal
biofilm development [29,30]. While homogeneous cultures of pili
mutants are deficient in biofilm formation [31], mixtures of pili
mutants and wild-type cells form biofilms with the pili mutants
located predominately in the stalks of microcolonies [32].
Additionally, disruption of a different type of motility—
flagellum-based swimming—was beneficial specifically in the
planktonic enrichments without drug (Figure 2, cluster C1), likely
due to the high energetic cost of flagella synthesis and rotation
[33]. As cells in biofilms typically do not have flagella [34], and
cells lacking flagella are defective in the early stages of biofilm
formation [31], the lack of a functional flagella biosynthesis
pathway would be expected to be much less beneficial in biofilms.
Fitness Profiling via Direct Competition Assays
To better understand the contribution of the identified loci to
biofilm-mediated tobramycin tolerance, we chose 45 mutants from
University of Washington (UW) transposon insertion mutant
collection [35] based on the genome-wide footprinting data and
individually competed each against a differentially labeled P.
aeruginosa reference strain in a scaled-down version of the Bio-TOB
experiment described above. Mutants chosen belonged mainly to
clusters C4 and C6 of Figure 2A (see Protocol S1 and Figure S2 for
details). The reference strain served as an internal control for
experiment-to-experiment biofilm-formation variability, facilitated
between-strain comparisons, and helped mimic natural biofilm
conditions where mutants arise in the presence of the parental
strain. In order to focus on genes whose role in antibiotic tolerance
had not been previously characterized, genes identified in a
previous genome-wide study of low-level aminoglycoside resistance
[11] were excluded, except for three: nuoK (PA2646), nuoA
(PA2637), and wzm (PA5451), which were included as controls.
Twenty-three mutants demonstrated fitness changes—16 in-
creases and 7 decreases—in the Bio-TOB challenge beyond that
typical of the UW collection (see the ‘Competition Assays’ section
in the Protocol S1 document), and those mutants were then
subjected to similar competitions in Bio-ND and Pla-TOB
conditions (Figures 3 and S3). Our inability to replicate the
original library observations using the other 22 UW strains is likely
due to differences in transposon location and orientation between
the UW collection and the original transposon insertion library.
Spontaneous mutations in individual strains of the UW collection
as well as differences between the parental strains of the original
library and the UW collection, which are both MPAO1, might
also have contributed.
Among the sixteen mutants with substantially above-average
fitness in the Bio-TOB setting, the tobramycin resistance of two
strains, the PA3726 and PA0614 mutants, is specific to the biofilm
state. Neither performed markedly above-average in the Bio-ND
competitions; further analyses of these mutants are presented later.
The other 14 mutants displayed at least a mild to moderate
tobramycin tolerance in the planktonic state, suggesting that
similar pathways confer antibiotic tolerance in both the biofilm
and planktonic states (Figure 3A). As cultures in the planktonic
condition undergo different numbers of generations compared to
the biofilm setting, competition values from Bio-TOB and Pla-
TOB challenges for the same mutant are not directly comparable.
Interestingly, both nuoA and nuoK strains, which are among the
fittest in the Pla-TOB condition, have below-average fitness in the
Bio-ND condition. Thus, the relative fitness of nuoA and nuoK
mutants in the Bio-TOB setting in competition with a wild-type
strain is the result of a combination of two counteracting factors: a
general deficiency in biofilm formation and a survival advantage
upon exposure to tobramycin. Thus, the biofilm-formation defect
could explain why strains defective in oxidative phosphorylation
were enriched less strongly in the Bio-TOB library experiments
than in the Pla-TOB library experiments. Alternatively, although
both the planktonic and biofilm cultures were in sealed containers,
increased oxygen availability and usage in the planktonic cultures
may have decreased the comparative fitness of the wild-type strain
in Pla-TOB conditions [26].
Seven mutants demonstrated a fitness defect in the Bio-TOB
competitions (Figure 3B), suggesting that the corresponding
transposon insertions enriched in the original library caused
over-expression, rather than deletion, phenotypes. Consistent with
this hypothesis, the group includes PA2493 (mexE, multidrug efflux
membrane fusion protein [36]) whose over-expression is known to
cause a multi-drug resistance phenotype [37].
Increased Biofilm Tobramycin Tolerance Is Not
Associated with Slow Growth in the Planktonic State
Since fast growing bacteria are more susceptible to antibiotics
[38], we generated growth curves in the absence of drug for all 23
strains to determine if an inherently slow growth rate could
account for the observed antibiotic tolerance. Figure S4 shows that
during the first twelve hours of growth without tobramycin, all of
the strains display growth patterns similar to the reference strain,
suggesting that exponential phase growth differences are not a
major contributor to the observed antibiotic tolerance changes.
To further characterize the antibiotic susceptibility of the strains
in the planktonic state, we also generated growth curves for the
mutants with 4 and 8 mg/ml tobramycin. With 4 mg/ml
tobramycin, half the concentration typically used in this work,
the growth rates observed were generally consistent with the fitness
measured in the Pla-TOB competitions. Notably, the two mutants
(PA3726, and PA0614) that out-competed the reference strain in
the Bio-TOB, but not the Pla-TOB competitions, do not exhibit
any detectible planktonic growth rate advantage in 4 mg/ml of
tobramycin (Figures 3C and S5), which provides complementary
evidence that these mutants have average planktonic tobramycin
tolerance. With 8 mg/ml tobramycin, the density of most cultures
plateaued at less than 20% of the density obtained without drug
(Figure S6). The growth curves indicate that the majority of the
mutants selected for characterization have a moderate growth
advantage over the reference strain in Pla-TOB conditions. As
shown in Figure S6, the advantage, however, is far less
pronounced than that exhibited by many well-characterized
antibiotic-tolerant mutants, such as nuoA and nuoK strains (NADH
dehydrogenase I mutants). While our genome-wide screen
identified many loci previously known to cause strong antibiotic
tolerance [11], they were largely excluded from the final set in
order to focus on genes whose role in antibiotic tolerance had not
been previously characterized.
The growth kinetics of the strains with 4 mg/ml and 8 mg/ml of
tobramycin (Figures S5 and S6) suggests that the minimum
inhibitory concentration (MIC) of most of the mutants analyzed is
within 2-fold of that of the wild-type strain. Disk susceptibility
assays conducted on a subset of the mutants (PA0748, nuoK,
Antibiotic Tolerance in P. aeruginosa Biofilms
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inhibition indistinguishable from the reference strain (data not
shown). Kill curves for monocultures of the same set of mutants in
biofilm and planktonic settings (Figure S7) indicate that 4 of the 6
strains behave similarly to the reference strain in biofilms and are
slightly more resistant in planktonic cultures; the nuoK strain is less
susceptible in both conditions while the PA4516 mutant is more
susceptible. The substantial behavioral differences between
competition and traditional homogeneous culture assays, com-
bined with the former’s similarity to clinical settings, argue that the
field should strive to incorporate mixed-population tests into the
standard battery. Furthermore, as many of the mutations analyzed
likely affect different pathways, strains that accumulate multiple
mutations of small effect may exhibit clinically relevant levels of
resistance [27,39].
Assigning Individual Genes to Biological Processes and
Pathways
To better understand the biological pathways and processes that
contribute to enhanced biofilm tolerance to antibiotics, we used a
combination of experimental and computational approaches to
classify the candidate loci into functional classes. The altered
tobramycin susceptibility of nine of the 23 mutants analyzed is
likely due to modulation of one of three processes previously
implicated in antibiotic tolerance: quorum-sensing, oxidative
phosphorylation, and membrane permeability (Table S3). The
other mutants likely modify pathways not examined here, such as
LPS composition [11], or employ novel mechanisms of action.
Oxidative phosphorylation. One of the first symptoms of a
lethal dose of bactericidal antibiotics is increased oxidation of
NADH through the electron transport chain [26], and P. aeruginosa
strains with defects in energy metabolism, the NADH
dehydrogenase complex, or cytochromes are more tolerant of
tobramycin [11]. Therefore, we wanted to determine if any of the
mutants identified have abnormal NADH/NAD
+ ratios. As
NADH dehydrogenase mutants are particularly fit in Pla-TOB
challenges, we focused on the mutants with the most pronounced
growth advantage with tobramycin in the planktonic state. In
addition to the positive control, nuoK, three mutants (PA1329,
PA3966, and PA5207) have an elevated NADH/NAD
+ ratio
compared to the wild-type strain (Figures 4A and S8), which could
explain why these mutants are more tolerant of tobramycin in
both the planktonic and biofilm states.
Figure 3. Fitness characterization of candidate mutants in different physiological states. (A, B) Competitions were started with equal
amounts of mutant and reference cells. The y-axis indicates the relative count of mutants over the reference strain following one round of the
indicated experimental challenge (as explained in Materials and Methods). As cultures undergo different numbers of generations during each type of
challenge, values from different challenges for the same mutant are not directly comparable. Error bars indicate the standard error of at least 8, 4, and
3 experiments for the Bio-TOB, Bio-ND, and Pla-ND conditions, respectively. Mutants in (A) have an advantage over wild-type in the Bio-TOB
competition; mutants in (B) have a disadvantage. Gene annotations, which were updated from the original genome annotation [48] by BLAST
comparisons [14] against the NCBI non-redundant database, are in Table S3. (C) Growth curves for representative strains from panels (A) and (B) with
4 mg/ml tobramycin are shown.
doi:10.1371/journal.ppat.1002298.g003
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candidate mutants have abnormal membrane permeability or
increased susceptibility to the disruptive activity of aminogly-
cosides, we used a 1-N-phenylnaphtylamine (NPN) assay [11,40].
NPN is a fluorescent probe that has weak fluorescence activity in
aqueous solutions but fluoresces substantially in non-polar or
hydrophobic environments such as membranes. In the absence of
membrane-disruptive stress, NPN has limited access to the outer
membrane and shows minimal activity. The introduction of
tobramycin, however, compromises outer membrane integrity,
allowing more NPN to leak into the interior section of the
membrane, leading to increased fluorescence.
The NPN assay indicates that PA1723 (pscJ, type III export
protein mutant) has a compromised membrane and that the
membrane of PA3844 is unusually impermeable (Figure 4B). The
behavior of the remaining mutants tested was indistinguishable
from the wild-type (Figure S9). This could explain why PA1723
mutants have a relative fitness disadvantage in the presence of
tobramycin while PA3844 mutants have an advantage.
Quorum sensing. Although others have observed quorum
sensing-deficient P. aeruginosa to be more sensitive to various
antimicrobial agents, including tobramycin [15], in this work, two
quorum sensing-deficient mutants, lasR (PA1430), which encodes a
transcriptional regulator, and rhlI (PA3476), which encodes an
auto-inducer synthesis protein, displayed fitness advantages in
biofilms exposed to tobramycin. This apparent discrepancy may
be explained by the ability of some quorum sensing mutants to act
as cheaters in mixed populations, allowing the mutants to reap
some of the population benefits of quorum sensing without sharing
the metabolic burden of activating quorum-sensing downstream
processes (see [41] for an example).
A similar situation involving indole, a different signaling
molecule, was recently reported [42]. In that case, a small number
of resistant mutants produced indole at a fitness cost to them-
selves. The more sensitive members of the population then sensed
the indole and increased production of efflux pumps and
oxidative-stress protections, increasing their resistance beyond
that exhibited in a homogeneous population.
To investigate whether any of our other mutants of interest
perturb the quorum sensing circuitry, we transferred reporter
plasmids for each of the two quorum sensing systems to all mutants
except those whose annotations suggested a low likelihood of
involvement in quorum sensing. As shown in Figures S10 and S11,
in addition to the lasR and rhlI strains, only one strain, the PA1732
mutant, which has low activity in both the rhl and las systems, was
distinguishable from wild-type. Unlike the lasR and rhlI strains,
however, the PA1732 mutant performs poorly in Bio-TOB
competitions, possibly due to pleiotrophic effects from disrupting
PA1732, which encodes a transglutaminase-like domain contain-
ing protein.
Microarray expression meta-analysis. To determine if
subsets of the genes of interest are co-expressed, and hence more
likely to function together, we did a meta-analysis of 255 published
expression arrays (See Materials and Methods). The available
data, which consist of the response to a variety of stresses and
growth conditions in several different genetic backgrounds,
contain three main expression classes (Figure S12). The first
class contains 2701 genes involved in core metabolic processes
including translation, lipid A and nucleotide synthesis, tRNA and
rRNA processing, and DNA replication (Figure S13). The second
class consists of 2527 genes enriched in type II secretion,
cytochrome c oxidase activity, and periplasmic processes. The
remaining 320 genes have expression patterns related to each
other only weakly. Of the 23 genes of interest, 8 are expressed with
the first class, 12 with the second, and 3 with the third, which is
consistent with the distribution expected by chance (Figure S14).
This indicates that the genes whose disruption affects fitness in
biofilms in the presence of tobramycin are not all co-regulated.
Additionally, we used iPAGE to identify functional categories
significantly correlated or anti-correlated with each gene of interest
at the transcriptional level. While the three large transcriptional
classes shown in Figure S12 explain most of the observed patterns,
Figure 4. Functional classification of genes associated with antibiotic tolerance in biofilms. (A) The NADH/NAD
+ ratio was measured for a
subset of mutants with the most pronounced growth advantage in the planktonic state with tobramycin. The NADH/NAD+ ratios for the strains
shown are significantly higher than wild-type (Student’s one-sided t-test p-values: 0.02, 0.002, 0.001, and 0.015 for mutants in PA1329, PA3966,
PA5207, and nuoK, respectively). Error bars represent the standard error of at least three replicates. (B) The disruptive effect of tobramycin on the
outer membrane of different mutants was measured using an NPN assay. NPN and tobramycin were added at the indicated times.
doi:10.1371/journal.ppat.1002298.g004
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interest is the correlation of PA2771 (diguanylate-cyclase with
GAF domain) expression with genes involved in drug response (p-
value =1610
25) (Figure S15). It is generally believed that high
levels of c-di-GMP increase extracellular matrix formation [43],
and c-di-GMP helps induce biofilm growth in response to low
levels of tobramycin [14]. Based on this generic model, disruption
of PA2771 would be expected to be deleterious in the Bio-ND
setting, which agrees with the competition data (Figure 3A).
Functional Characterization of Loci with Biofilm-Exclusive
Tobramycin Fitness Advantages
The PA0614 mutant is one of two strains with a fitness
advantage exclusive to the drug-exposed biofilm state. PA0614 is
up-regulated by ciprofloxacin challenge [44], has a hydrophobicity
profile similar to holins [44], and, as judged by BLAST e-values, is
homologous to holins from other Pseudomonas species.
To establish that PA0614 is involved in cell lysis, as would be
expected for a holin, the PA0614 ORF was cloned downstream of
an arabinose-inducible promoter on the low copy number vector
pJN105 [45]. Over-expressing PA0614 by adding arabinose to the
growth medium lead to increased cell lysis (Figure 5A).
To characterize the role of PA0614 in biofilms, we made a
transcriptional fusion of the PA0614-upstream-region to gfp.A sa
control, we first determined that the promoter fusion is, as
expected, ciprofloxacin-inducible (Figure S16). Next, we measured
PA0614 promoter activity in biofilms and planktonic cells and
found that the promoter is almost twice as active in biofilms as in
planktonic cells, independent of the presence or absence of
tobramycin (Figure 5B). In contrast, the promoter of a random
gene, PA3057, did not show state-dependent expression when
subjected to the same assay (Figure S17). Thus, the PA0614 gene’s
increased transcription in biofilms combined with the product’s
lethal activity, which may synergize with other stresses such as
tobramycin treatment, could account for why PA0614 mutants
have a competitive advantage specifically in biofilms challenged
with tobramycin.
The second mutant we found to have a biofilm-specific
tobramycin tolerance has a transposon insertion in PA3726,
which encodes a hypothetical protein homologous to the Salmonella
typhimurium protein YaeQ. In Escherichia coli and S. typhimurium,
YaeQ has been reported to be a suppressor of mutations in rfaH,
an anti-terminator required for full-length expression of some
virulence factor operons [46], although those findings are not
without controversy [47].
In order to better understand the biological function of PA3726,
we examined the exponential-phase, planktonic mRNA expression
of a PA3726 mutant. As shown in Figure 5C, we found that the
Figure 5. Characterization of loci conferring biofilm-specific tobramycin tolerance. (A) The MPAO1 strain with either an empty vector or a
plasmid containing PA0614 under the control of an arabinose-inducible promoter was grown in M63 medium in the presence and absence of 0.2%
arabinose (Ara). (B) A gfp promoter fusion was used to measure the expression of PA0614 in both biofilm and planktonic settings, in the presence and
absence of 8 mg/ml tobramycin. Promoter activities are normalized by colony forming units (CFU). (C) Expression differences between exponentially
growing cultures of wild-type and PA3726 mutant cells were sorted and partitioned into 20 equally populated bins, which were subjected to iPAGE
analysis. The most informative functional categories are shown. (D) PA3726 promoter activity was measured as described in (B).
doi:10.1371/journal.ppat.1002298.g005
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NADH dehydrogenase activity (e.g., nuoI, nuoF, and nuoM) and
cofactor biosynthetic processes (e.g., cobU, cobB, and cbiD, which
are involved in cobalamin synthesis) and increased expression of
secretion and pathogenesis genes (e.g., exoY, pscU, and exsC).
Using a gfp transcriptional-fusion reporter construct, we found
that PA3726, similar to PA0614, is transcribed more actively in
biofilms than planktonic cultures, independent of the presence or
absence of tobramycin (Figure 5D). Since PA3726 is expressed
more highly in biofilms than planktonic cells, disruption of
PA3726 likely has a larger effect in the biofilm state. As PA3726
disruption reduces expression of genes encoding NADH dehydro-
genase activity (Figure 5C), the relative decrease in oxidative
phosphorylation and increase in tobramycin resistance is likely
larger in the biofilm state. Thus, taken together, our results suggest
that disrupting PA3726 could reduce NADH dehydrogenase
expression preferentially in biofilms, conferring biofilm-specific
tobramycin tolerance.
Discussion
To better understand the role of cellular state and gene-
environment interactions in antibiotic tolerance, we examined the
relative importance of each gene in P. aeruginosa to fitness in the
presence of tobramycin as a function of whether the bacterium is
living in a biofilm or growing planktonically. Several previous
studies identified a small number of P. aeruginosa genes whose
contribution to antibiotic tolerance depends on whether the cells
are in a biofilm or planktonic state [16,17,18], but this work
represents a substantially more comprehensive and systematic
examination of the question. Here, we competed the mutants in a
transposon library en masse in each of four conditions: biofilms with
and without tobramycin, and planktonic growth with and without
tobramycin. We then characterized the changes in the population
by genetic-footprinting and microarray hybridization.
All the biofilms were formed on plastic slides under static
conditions with limited oxygen availability, likely creating micro-
aerobic conditions. Cellular physiology in oxygen-limited biofilms
is clinically relevant as during chronic, late-stage cystic fibrosis, P.
aeruginosa grows under reduced oxygen tension and is capable of
respiring anaerobically within the thickened airway mucus [48].
Although it is well-known that the biofilm state increases drug
tolerance [4], we find that the strains that are most fit in biofilm
environments do not necessarily have higher antibiotic tolerance.
In fact, our population-level data shows that the set of mutants
with high fitness in biofilms (not exposed to tobramycin) has
minimal overlap with the set of mutants with high fitness in
biofilms in the presence of tobramycin. This implies that the
general resistance provided by a biofilm against antibiotics does
not protect all members equally and that genetic factors contribute
to fitness in the biofilm context.
Moreover, while there is a considerable overlap between the loci
that modulate antibiotic tolerance in biofilm and planktonic cells,
the relative importance of most genes is state-specific. For
example, the vast majority of mutants with the strongest fitness
advantages in the biofilm state also have only a weak to moderate
advantage in the planktonic state. Such strains, however, perform
poorly in planktonic tobramycin challenges when in complex
mutant populations due to the presence of a myriad of other
strains, such as NADH dehydrogenase mutants, with more
pronounced planktonic drug tolerance capacities. Similarly, while
NADH dehydrogenase mutants are among the fittest strains in
planktonic tobramycin challenges, these mutants exhibit only a
comparatively moderate advantage in biofilms exposed to
tobramycin. We expect that such differential fitness reflects not
only the physiological state of the cells but also environmental
differences, such as lower oxygen availability.
To better understand the pathways contributing to tobramycin
tolerance in biofilms, we undertook a broad characterization of a
subset of the strains that demonstrated a fitness advantage in
biofilms in the presence of tobramycin and whose role in antibiotic
tolerance had not been previously identified. We found mutants
with changes in membrane permeability, quorum sensing, efflux
pump abundance, and oxidative respiration activity—changes
previously associated with planktonic antibiotic tolerance
[11,12,13,15]. Some mutants, however, did not show changes in
any of the above pathways, suggesting that additional mechanisms
are at play (Figure 6). One such mechanism that we did not
explore is conversion to the RSCV (Rough Small-Colony Variant)
state, which is associated with hyper-adherence to solid surfaces
and higher antibiotic tolerance [17,49].
As P. aeruginosa cells in microcolonies have elevated mutation
rates [50] and many clinical isolates of P. aeruginosa are
hypermutable [51], each population explores a large part of the
fitness landscape. In the course of this real-time evolution, each
new mutant starts as a minority and competes against the pre-
existing population. In this study, we attempted to capture some
elements of natural conditions by analyzing our library of mutants
as a heterogeneous pool rather than as homogeneous cultures of
individual mutants as has been done more commonly [11,16].
Each individual mutant was present at low abundance and was
tested for a fitness advantage or disadvantage within a diverse
population that was expected to function collectively as a wild-type
proxy.
Our choice of experimental paradigm leads to some important
discrepancies with previous works. For example, while Bjarnsholt
et al. showed that quorum sensing enhances tobramycin tolerance
in P. aeruginosa [15], our results indicate that some quorum sensing-
defective mutants have a fitness advantage in the presence of
tobramycin in competition with a quorum sensing-capable strain.
The cheating behavior of quorum-sensing mutants in a mixed
population [41] can explain the incongruity, and, indeed, quorum
sensing-deficient mutants, specifically lasR mutants, have been
frequently isolated from Pseudomonas–associated infections [24].
Hence, the mixed population approach utilized here, in both the
initial selections and the follow-up competitions, appears to
capture some real-world, biological phenomena not observed in
homogeneous cultures.
Efforts to develop effective therapeutic strategies against P.
aeruginosa infections can benefit from a thorough understanding of
how each gene contributes to the organism’s antibiotic tolerance in
the range of microenvironments present within an infection. We
hope that this work and future studies using similar tools in other
natural and clinical isolates will contribute to that effort.
Methods
Strains, Media, and Growth Curves
M63 media (100 mM potassium phosphate monobasic, 15 mM
ammonium sulfate, 1 mM magnesium sulfate, 1.7 mM ferrous
sulfate adjusted to pH 7.0 with potassium hydroxide and
supplemented with 0.3% glucose and 0.5% casamino acids) was
used for all experiments unless stated otherwise [17]. LB media
was 1% Bacto Tryptone, 0.5% yeast extract, and 0.5% sodium
chloride. Antibiotics were used as needed at the following
concentrations unless stated otherwise: 8 mg/ml for tobramycin,
200 mg/ml for carbenicillin, and 100 mg/ml for gentamicin.
Tobramycin was stored at -20uC in single use aliquots. Strains
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aeruginosa mutants were in the MPAO1 strain background. All
growth curves were done in a SynergyMx plate reader (Biotek); see
Protocol S1 for details.
Transposon Construction and Mutagenesis
Transposon mutagenesis of strain MPAO1 (SAH001) was
carried out via a bi-parental conjugation with an E. coli S17–1
l-pir donor strain carrying the mariner transposon construct on
plasmid pBTK-MAR2xT7. Based on estimates from plating small
aliquots immediately after the cells were scraped off the mating
plates, the library contained ,2610
6 independent transposon
insertion mutants.
Library Enrichments
Planktonic and biofilm experiments were all started with
,1610
8 cells from the transposon library. In all planktonic
experiments, tubes were shaken at 250 rpm; for biofilm enrich-
ments, a sterile, plastic slide was provided as the biofilm formation
substrate and cultures were not shaken. Approximately 4.7610
6
cells colonize every square millimeter of the slide (standard error
=1.3610
6 of three experimental replicates). All the experiments
were carried out at 37uC. For each round of enrichment, cultures
were grown for 24 hours without tobramycin (initiation phase).
Then a fraction of the old culture (for planktonic experiments) or
the slide (for biofilm experiments) was transferred to fresh media
either with or without tobramycin and grown for an additional
24 hours (selection phase). After 24 hours, a similar transfer was
done to fresh media with no drug (recovery phase). This was
followed by a second round of selection and recovery phases.
Enriched populations were harvested by centrifugation and stored
at -80uC. For biofilm samples, cells were removed from the slides
by vigorous shaking and vortexing prior to centrifugation. For
more details, see Protocol S1.
Genetic Footprinting and Sample Preparation for
Microarray Hybridization
DNA manipulations were similar to those described before [23]
with some alterations. In brief, genomic DNA was isolated from
frozen cell pellets using the QIAamp DNA Mini Kit (Qiagen),
digested with a combination of BsaHI/ClaI/BstBI/AclI, NarI/
HpyCH4IV, and HinP1I in three parallel reactions, and ligated to
a Y-shaped linker [23]. Next, the ligation product was used as a
template to amplify the DNA adjacent to both ends of the
transposon. PCR product was transcribed in vitro using T7 RNA
polymerase, reverse transcribed into biotin-labeled cDNA, frag-
mented to approximately 50–200 bp using DNase I, and
hybridized to GeneChip P. aeruginosa Genome Arrays (Affymetrix).
More detail is provided in the Protocol S1 document.
Analysis of Microarray Footprinting Data
Probes that contained the recognition sites of restriction
enzymes belonging to at least two of the following restriction
enzyme sets (BsaHI/ClaI/BstBI/AclI, NarI/HpyCH4IV, or
Figure 6. Mechanisms for altering biofilm-mediated antibiotic tolerance. Shown are pathways that the genes from Figure 3A and 3B likely
use to modulate biofilm-mediated antibiotic tolerance in P. aeruginosa. The ‘‘*’’ indicates that the altered antibiotic-susceptibility is specific to the
biofilm state. Genes in the ‘Other’ category likely affect uncharacterized pathways or pathways not assayed in this work.
doi:10.1371/journal.ppat.1002298.g006
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was the average of the perfect match minus mismatch differences
from the rest of the probes for the gene. Data from different arrays
were sum-normalized prior to comparison (Dataset S1).
Competition Assays
The identities of mutants from the UW collection [35] were
verified by PCR using one primer from the transposon and one
from the P. aeruginosa genome. Different mutants and the reference
strain were labeled with a chromosomal copy of e-yfp or e-cfp,
respectively, using broad host-range mini-Tn7 vectors [52]. To start
a competition, roughly equal numbers of the CFP-labeled reference
strain (SAH349) and the YFP-labeled mutant were mixed in a 2 ml
tube. For planktonic competitions, the tube was shaken at 250 rpm;
for biofilm competitions, the tube contained a piece of plastic slide
and was not shaken. Similar to the library enrichment procedure,
cells were taken through one cycle of initiation, selection, and
recovery. At the end of the third day (i.e., the recovery phase), cells
were harvested and grown to late exponential phase in order to
obtain sufficient signal and to minimize the contribution of non-
viablecells.Finally,theCFP(excitation:433 nm,emission:475 nm)
and YFP (excitation: 510 nm, emission: 532 nm) signals were
measured in the culture, using a SynergyMx plate reader to
determine the abundance of each strain in the population. See the
Protocol S1 document for more details.
Disk Susceptibility Assays
Tobramycin impregnated disks (BD product #231569) were
placed on LB plates that had been spread with 200 ml of overnight
LB-grown cultures that had been diluted 100-fold. Zones of
inhibition were measured after 24 h of incubation at 37uC.
NAD Cycling Assay
Overnight, M63-grown cultures were diluted 1:100 into fresh
M63. When the cultures reached mid-log phase, two 1 ml
samples, one each for NAD
+ and NADH extractions, were
harvested by spinning in a table-top centrifuge at maximum speed
for 30 seconds. Supernatant was removed, and pellets were snap-
frozen in an ethanol-dry ice bath. The Fluoro NAD
TM kit (Cell
Technology Incorporation) was used to determine NAD
+ and
NADH content, according to the manufacturer’s instructions.
Tobramycin-Outer Membrane Interaction Study
Cells were harvested from 1 ml mid-log phase cultures by
centrifugation and re-suspended in 5 mM HEPES buffer, pH 7.2,
supplemented with 5 mM carbonyl cyanide m-chlorophenylhydra-
zone. NPN (final concentration of 50 mM) and tobramycin (final
concentration of 8 or 0 mg/ml) were added after 1 and 3 minutes,
respectively, and incorporation of NPN into the membrane was
measured in a SynergyMx plate reader using an excitation
wavelength of 350 nm and an emission wavelength of 420 nm.
Microarray Expression Meta-Analysis
P. aeruginosa expression datasets were downloaded from the
GEO (Gene Expression OmniBus) database (See the Protocol S1
document for the full list). All the expression datasets were sum
normalized, and missing values were estimated using a weighted
K-nearest neighbor method (KNNimpute) [53]. Then, for each
gene, x, in the genome and each gene, y, from Figure 3A and 3B,
the Pearson’s correlation coefficient between the expression
profiles for6and y was calculated. Finally, the correlation
coefficients were clustered using a K-means algorithm with a
Euclidean distance metric [54].
Expression Analysis
RNA was isolated from mid-exponential phase cultures of
SAH084, SAH087, SAH108, and SAH502, converted to cDNA,
fragmented, labeled with biotin, and hybridized to Affymetrix
GeneChip P. aeruginosa Genome Arrays. Additional details are
provided in Protocol S1. Complete data is provided in Dataset S2
and also deposited in the Gene Expression Omnibus (GEO)
database with the accession number GSE26142.
iPAGE Analysis
iPAGE was run locally using GO categories from Pseudocyc
[55] and GOanna [56].
Accession Numbers
Expression data from this work are archived in the GEO
database with accession number GSE26142.
NCBI accession numbers for the genes and proteins mentioned
in the text are provided below:
PA0614, 880722; PA0748, 879324; PA1329, 880896; lasR,
881789; pscJ, 881901; PA1732, 878043; rbsB, 878276; mexE,
880212; nuoA, 882344; nuoK, 882355; PA2653, 882362; PA2771,
882750; PA3048, 882879; PA3222, 882553; rhlI, 878967; PA3726,
880374; purT, 880455; PA3844, 879831; PA3966, 878878;
PA4175, 880208; PA4516, 881122; PA5207, 879542; wzm,
883118.
Supporting Information
Dataset S1 Hybridization signals from transposon
library enrichments and the original, unselected li-
brary.
(XLS)
Dataset S2 Mid-exponential phase expression data
from the PA3726 mutant (SAH108) and three MPAO1
isolates.
(XLS)
Dataset S3 Clusters of genes whose modulation or
disruption by transposons differentially altered fitness
among different experimental conditions.
(XLS)
Figure S1 Viability of planktonic and biofilm cultures
exposed to tobramycin. Both planktonic and biofilm samples
were started with 1:100 dilutions of overnight SAH001 cultures in
M63 media. In all planktonic experiments, tubes were shaken at
250 rpm; for biofilm experiments, a piece of sterile, plastic slide
was provided as the biofilm formation substrate and cultures were
not shaken. All the experiments were carried out at 37uCi n1m l
of media in a close 2 ml microfuge tube. Cultures were grown for
24 hr without tobramycin (initiation phase). Then, 10 ml of the
culture (for planktonic experiments) or the slide (for biofilm
experiments) was transferred to 1 ml of fresh media either with or
without tobramycin and grown for an additional 24 hr (selection
phase). After 24 hr, cells were harvested (for biofilm samples, cells
were removed from the slides by vigorous shaking and vortexing)
and cell counts were acquired by plating serial dilutions on LB
plates. The reported number is the average of 5 experimental
replicates for each sample, which is in a total volume of 1 ml.
Error bars correspond to the standard error. CFU: colony-forming
units.
(PDF)
Figure S2 Competitive enrichment data for 45 genes
selected for further analysis. Shown is the genome-wide
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PLoS Pathogens | www.plospathogens.org 10 October 2011 | Volume 7 | Issue 10 | e1002298footprinting data for the 45 genes chosen for further analysis. See
the ‘Competition Assays’ section of Protocol S1 for selection
criteria. Genes (rows) were arranged using hierarchical clustering,
and the hybridization scores shown for each gene were mean-
centered and normalized to a standard-deviation of one. Column
labels indicate the experimental condition: Bio-ND and Bio-TOB
refer to transposon insertion libraries grown as a biofilms and
treated with no drug or tobramycin, respectively, and Pla-ND and
Pla-TOB refer to libraries grown planktonically without or with
tobramycin. Two biological replicates were performed in each
condition, and numbers indicate the repetition number. Yellow
(blue) indicates that transposon insertions were beneficial (delete-
rious) in the experimental condition.
(PDF)
Figure S3 Fitness in Bio-TOB competitions of candidate
mutants not chosen for further analysis. Competitions
started with equal amounts of mutant and reference cells. The y-
axis indicates the relative amounts of cells following the
experimental challenge (as explained in Methods). Error bars
indicate the standard error of at least 8 experiments.
(PDF)
Figure S4 Growth curves with 0 mg/ml tobramycin.
Shown are growth curves for all strains in Figures 3A and 3B in
the absence of tobramycin.
(PDF)
Figure S5 Growth curves with 4 mg/ml tobramycin.
Shown are growth curves for all strains in Figures 3A and 3B
with 4 mg/ml tobramycin.
(PDF)
Figure S6 Growth curves with 8 mg/ml tobramycin.
Shown are growth curves for all strains in Figures 3A and 3B
with 8 mg/ml tobramycin.
(PDF)
Figure S7 Kill curves in the planktonic and biofilm
states. Both planktonic and biofilm tests were conducted at 37uC
in closed 2 ml microfuge tubes with 1 ml of media. Experiments
were started with 1:100 dilutions of overnight cultures grown in
M63 media. (A) For the planktonic experiments, overnight
cultures were added to fresh media with 8 mg/ml of tobramycin
(or 0 mg/ml tobramycin for the no drug control). Tubes were
shaken at 250 rpm and viability was measured at the indicated
times by plating serial dilutions of the cultures. (B) For biofilm
experiments, a sterile, plastic slide was provided as the biofilm
formation substrate and cultures were not shaken. Cultures were
grown for 24 hr without tobramycin to allow biofilms to form.
Then, the slide was transferred to 1 ml of fresh media with 8 mg/
ml tobramycin (or 0 mg/ml tobramycin for the no drug control)
and grown for the indicated time. To harvest the biofilm samples,
the slides were moved into PBS and the cells were removed from
the slides by vigorous shaking and vortexing. Cell counts were
acquired by plating serial dilutions on LB plates. Numbers are the
average of at least 3 and 4 experimental replicates for the
planktonic and biofilm settings, respectively. Error bars show the
standard error. CFU: colony-forming units, ND: no drug. The
following strains were used: SAH020 (PA0748), SAH027 (PA2646,
nuoK), SAH032 (PA2771), MPAO1 (SAH084), SAH110 (PA4516),
SAH114 (PA2653), and SAH129 (PA3966).
(PDF)
Figure S8 Complete data for NAD cycling assay. The
NADH/NAD
+ ratio was measured in the following mutants that had
the most pronounced growth advantage in the planktonic phase:
SAH018 (PA1329), SAH041 (PA3476, rhlI), SA087 (MPAO1),
SAH116 (PA3048), SAH124 (PA3844), SAH128 (PA3222),
SAH129 (PA3966), SAH130 (PA5207), and SAH027 (PA2646, nuoK).
(PDF)
Figure S9 Complete data for tobramycin-outer mem-
brane interaction assay. As explained in the Methods section,
the interaction of tobramycin with the outer membrane was
measured using an NPN assay in the following strains: SAH018
(PA1329), SAH020 (PA0748), SAH032 (PA2771), SAH087
(MPAO1), SAH110 (PA4516), SAH112 (PA1732), SAH114
(PA2653), SAH116 (PA3048), SAH121 (PA2493, mexE),
SAH124 (PA3844), SAH127 (PA1723, pscJ), SAH128 (PA3222),
SAH129 (PA3966), SAH130 (PA5207), SAH318 (PA1946, rbsB),
SAH320 (PA3751, purT), and SAH328 (PA4175). NPN (final
concentration of 50 mM) and tobramycin (final concentration of
8 mg/ml) were added after 60 and 180 seconds, respectively. Error
bars show the standard deviation of the data from all the mutants
shown.
(PDF)
Figure S10 Complete data for lasR reporter activity.
Quorum sensing reporter plasmid pGJB6 (rsaL:gfp, lasR reporter)
was used to monitor the activity of the las quorum sensing system
in all mutants except those whose annotations suggested a low
chance of quorum-sensing involvement.
(PDF)
Figure S11 Complete data for rhlR reporter activity.
Quorum sensing reporter plasmid pYL121 (rhlAB:gfp, rhlR
reporter) was used to monitor the activity of the rhl quorum
sensing system in all mutants except those whose annotations
suggested a low chance of quorum-sensing involvement.
(PDF)
Figure S12 Expression data places P. aeruginosa genes
into three global classes. Each row corresponds to a gene in
the P. aeruginosa genome for which expression data was available;
each column corresponds to a gene whose disruption was
confirmed to affect fitness in the Bio-TOB setting (Figure 3A,
3B). The colors represent the Pearson’s correlation coefficient of
the expression profiles for the pair of genes.
(PDF)
Figure S13 iPAGE meta-analysis of expression data.
Using iPAGE, we searched for functional enrichments or
depletions in each of the three classes from Figure S12.
(PDF)
Figure S14 Genes whose disruption alters Bio-TOB
fitness are not all co-expressed. As in Figure S12, colors
represent the Pearson’s correlation coefficient of the expression
profiles for the pair of genes. Genes were arranged by hierarchical
clustering. Shown are the genes whose disruption by transposon,
substantially altered fitness in the Bio-TOB setting (Figure 3A, 3B).
(PDF)
Figure S15 Functional relationships between PA2771
expression and genome-wide expression. Pearson’s corre-
lation coefficients comparing the expression of all genes to the
expression of PA2771 were subjected to iPAGE analysis to detect
over- and under-represented functional categories in each range of
correlation. Expression data came from the same 255 published
expression arrays used for Figures S12, S13, and S14.
(PDF)
Figure S16 Ciprofloxacin induction of PA0614 promot-
er. In order to control for the functionality of the PA0614’-gfp
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were grown in the presence of different ciprofloxacin concentra-
tions and (A) the promoter activity (gfp fluorescence) and (B) the
culture density (absorbance) were measured.
(PDF)
Figure S17 PA3057 promoter activity. PA3057 promoter
activity was measured using a gfp fusion reporter in both biofilm
and planktonic settings in the presence or absence of 8 mg/ml
tobramycin. No significant difference was observed in the
promoter activity in any of these different settings. Promoter
activities are normalized by colony forming units (CFU).
(PDF)
Protocol S1 A more detailed description of the protocols
and methods.
(DOC)
Table S1 Strain table. List of all strains used in this study.
(XLS)
Table S2 Plasmid table. List of all plasmids used in this study.
(XLS)
Table S3 Summary of genes with altered fitness in the
Bio-TOB assay that were subjected to further charac-
terization. Shown are the PA#s, annotations, and predicted
pathway of action (if available) for genes whose disruptions alters
fitness in the Bio-TOB assays of Figure 3A and 3B.
(XLS)
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